Thomas E. Hutson, DO, PharmD, and Chung-Han Lee, MD, PhD, remark on the potential for treating patients with metastatic renal cell carcinoma with a combination of lenvatinib and everolimus in various clinical settings, based on emerging evidence in the field.
